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LETTER
Adaptive deep brain
stimulation for Parkinson’s
disease demonstrates reduced
speech side effects compared
to conventional stimulation
in the acute setting
INTRODUCTION
Deep brain stimulation (DBS) for
Parkinson’s disease (PD) is currently
limited by costs, partial efﬁcacy and surgi-
cal and stimulation-related side effects.
This has motivated the development of
adaptive DBS (aDBS) whereby stimulation
is automatically adjusted according to a
neurophysiological biomarker of clinical
state, such as β oscillatory activity (12–
30 Hz). aDBS has been studied in parkin-
sonian primates and patients and has been
reported to be more energy efﬁcient and
effective in alleviating motor symptoms
than conventional DBS (cDBS) at matched
amplitudes.1 2
However, these studies have not consid-
ered whether side effects can also be
avoided with clinically effective stimula-
tion. In PD, it is well recognised that a sig-
niﬁcant proportion of patients develop
speech deterioration following DBS of the
subthalamic nucleus (STN), which may be
reversible.3
Here we test bilateral stimulation, opti-
mising parameters for aDBS, and evaluate
speech intelligibility. We hypothesised that
acute aDBS would be more effective and
more efﬁcient than cDBS at matched
stimulation parameters while causing less
speech impairment.
METHODS
We recruited 10 patients with advanced
idiopathic PD following implantation of
DBS electrodes into the STN.2 Recordings
took place 3–6 days following electrode
placement during a temporary period of
externalisation. All participants gave
informed written consent, and were tested
following overnight withdrawal of dopa-
minergic medication (see online
supplementary material). Two patients
were excluded due to external stimulator
failure leading to no voltage delivery
under aDBS and cDBS conditions.
aDBS stimulation was delivered bilat-
erally, only when β amplitude exceeded a
threshold as previously described.2 aDBS
contacts, voltages and trigger thresholds
were independently set for the two sides
according to motor beneﬁt versus induced
paraesthesiae, with the same contacts/vol-
tages used for cDBS.
Stimulation in each block continued for
15 min prior to evaluation. Participants
were assessed during blinded and rando-
mised aDBS, cDBS and OFF conditions
using the standardised and validated
speech intelligibility test (SIT) in which
participants read sentences totalling 110
words.4 5 Speech was recorded, and %
intelligibility was assessed by a speech and
language therapist (blinded to condition).
Six of the eight participants completed an
MDS-UPDRS-III assessment, which was
videoed and rated off-line (rigidity
excluded, vUPDRS total=112) by two
blinded movement disorder specialists.
Two participants did not perform the
MDS-UPDRS-III assessment due to
fatigue/discomfort related to prolonged
off states. Our primary outcome measures
were a comparison of aDBS with cDBS
for speech (SIT), and for motor impair-
ment (vUPDRS). Statistical testing was
performed by repeated measures ANOVA
(rmANOVA) and the Student’s t-test.
RESULTS
The mean voltage (ﬁxed across cDBS and
aDBS) was 2.7±0.2 V, with stimulation in
the aDBS condition delivered 42.6±3.7%
of the time.
Speech scores
Baseline SIT scores OFF medication were
67.9±9.2%. rmANOVA (Off DBS, aDBS
and cDBS) demonstrated a signiﬁcant
main effect of stimulation type
(F2=4.153, p=0.038). Our planned con-
trast demonstrated better speech intelligi-
bility with aDBS (70.4±6.4%) than with
cDBS (60.5±8.2%; t7=2.8, ptwo tailed-
=0.02; ﬁgure 1). In secondary explora-
tory comparisons, aDBS was no different
to off DBS, but cDBS was worse than off
DBS (t
7
=2.55, ptwo tailed=0.038).
Motor scores
Baseline vUPDRS-III scores, OFF medica-
tion, were 28.8±4.5 (6 participants). This
was compared to a mean preoperative
score of 36.4, suggestive of a microle-
sional effect of surgery. The vUPDRS-III
score across the three conditions (Off
DBS, aDBS and cDBS) was compared by
rmANOVA (6 participants) and demon-
strated a signiﬁcant main effect of stimula-
tion (Fdf=2=5.4, p=0.025). Our planned
contrast revealed a signiﬁcant improve-
ment of aDBS compared to cDBS
(vUPDRS-III means: 19.7±1.0 vs 31.6
±4.3; t5=2.71, ptwo tailed=0.042).
DISCUSSION
Recent work has demonstrated that aDBS
may be more effective at improving motor
symptoms than conventional stimulation
in PD with stimulation amplitudes
Figure 1 (A) Bar chart showing the mean±SEM speech intelligibility across the three stimulation
conditions for all eight patients. (B) Data show individual percentage change for all participants
across stimulation conditions, normalised to the Off DBS state. aDBS, adaptive DBS; cDBS,
conventional DBS; DBS, deep brain stimulation; SIT, speech intelligibility test.
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optimised for cDBS.1 2 Here, we investi-
gate acute stimulation-induced speech
deterioration with parameters optimised
for aDBS contrasted with cDBS using
these same parameters. We found that in
this acute setting, the stimulation para-
meters optimal for aDBS signiﬁcantly
reduced reversible speech side effects and
improved motor function, whereas these
same stimulation parameters failed to
produce a beneﬁcial effect with cDBS and
led to impairment in speech intelligibility.
Together these ﬁndings suggest that stimu-
lation parameters adapted to aDBS may
potentially have a wider therapeutic
window than cDBS with the same para-
meters. This dual effect whereby aDBS
appears to have a lower efﬁcacy threshold
but spares speech may be related to the
temporal targeting of β bursts by
stimulation.
The average deterioration in the SIT
score when stimulated by cDBS as
opposed to aDBS was clinically relevant
(9.9%). For quantitative comparison, the
average deterioration when the STN is sti-
mulated at 4 V compared to 2 V is
reported as 16.5%,4 and the average
improvement with Lee Silverman Voice
Treatment was most recently reported as
4.7%.5
The present study has some acknowl-
edged limitations mostly stemming from
its acute nature in the postoperative
period resulting in a temporary microle-
sional effect. Consequently, the responses
to stimulation may not necessarily be rep-
resentative of the chronic state.
Furthermore, the postoperative period
also introduced time constraints and
patients were signiﬁcantly fatigued by
testing, and only short stimulation blocks
were performed that may have lessened
the mean effect of stimulation and
increased the variability. In addition, our
sample size was limited, and the use of
blinded video-based assessments, which
necessitates excluding rigidity scores and
provides smaller effect sizes than non-
blinded observations, may have obscured
beneﬁcial effects of cDBS. In sum, the
current study cannot conﬁrm whether
aDBS will prove more effective or toler-
able than independently optimised cDBS
in the chronic setting but does provide
proof of concept data that aDBS may, at
least acutely, have less propensity for
causing unwanted side effects than
cDBS.
In conclusion, our study provides the
ﬁrst blinded group data demonstrating
that aDBS has the potential to be more
efﬁcacious, with lower stimulation efﬁcacy
thresholds and less speech side effects
than cDBS, although this will need con-
ﬁrmation in trials in chronically implanted
patients.
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